Many people with locally advanced rectal cancer struggle because their tumors do not respond to standard immunotherapy. A new Phase 2 trial tested a different strategy by adding tislelizumab, a type of immune checkpoint inhibitor, to chemotherapy and radiation before surgery. The goal was to see if this combination could keep cancer from coming back.
Fifty patients enrolled in this multi-center study, and forty-six completed the full treatment plan. At the three-year mark, 89.1% of these patients remained disease-free. The study also found that twenty patients achieved a pathological complete response, meaning no cancer cells were left in the tissue samples after surgery. For those twenty people, the cancer did not return within three years.
Safety was a major focus during the long follow-up period. No new serious side effects occurred during the three years of observation. The trial offers a promising option for patients who might not respond to single-agent immunotherapy alone. However, this is a Phase 2 single-arm trial, so larger studies are needed to confirm these results before changing standard care.
